Clinical practice guidelines for management of disseminated intravascular coagulation in Japan 2024. Part 1: sepsis
- PMID: 39676120
- DOI: 10.1007/s12185-024-03896-9
Clinical practice guidelines for management of disseminated intravascular coagulation in Japan 2024. Part 1: sepsis
Abstract
The Japanese Society on Thrombosis and Hemostasis (JSTH) published the first-ever disseminated intravascular coagulation (DIC) guidelines in 2009. Fifteen years later, the JSTH developed new guidelines covering DIC associated with various underlying conditions. These guidelines were developed in accordance with the GRADE system to determine the strength of the recommendations and certainty of the evidence. This article was drafted as Part 1 of an overall DIC guideline covering various underlying conditions, with sepsis as the subject. In this section, seven key clinical issues (questions) are set. Question 1, regarding DIC diagnosis, introduces several diagnostic criteria, such as the JAAM-2, ISTH overt, SIC, and JSTH DIC criteria and recommends choosing the appropriate diagnostic criteria for DIC based on an understanding of their diagnostic properties. For pharmacotherapy in DIC patients with sepsis, we recommend the administration of antithrombin (Question 2) and recombinant thrombomodulin (Question 3) (both GRADE 1B). However, we do not make a clear recommendation regarding the administration of heparin (Question 6) and serine protease inhibitors (Question 7) because of the lack of evidence. Combination therapy, order of administration, and other administration methods for antithrombin and recombinant thrombomodulin are proposed as important future research questions (Questions 4 and 5).
Keywords: Antithrombin; DIC; Infection; Sepsis; Thrombomodulin.
© 2024. Japanese Society of Hematology.
Conflict of interest statement
Declarations. Conflict of interest: Kazuma Yamakawa has received research grants from the Japan Blood Products Organization and Asahi Kasei Pharma. Yoshinobu Seki was involved in clinical trials conducted by Chugai Pharmaceutical. Takashi Ito has received lecture fees and research grants from Asahi Kasei Pharma. Toshiaki Iba received a research grant from JIMRO. Hiroyasu Ishikura has received lecture fees from Asahi Kasei Pharma. Hideo Wada received a research grant from I.L. Japan. Hidesaku Asakura is editor of International Journal of Hematology. None of the authors have any potential conflicts of interest to disclose.
References
-
- Wada H, Thachil J, Di Nisio M, Mathew P, Kurosawa S, Gando S, et al. Guidance for diagnosis and treatment of DIC from harmonization of the recommendations from three guidelines. J Thromb Haemost. 2013;11(4):761–7. - DOI
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical